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roxaban describing good efficacy and safety.
Edoxaban has good efficacy and low complication 
for venous thrombosis [4]. One a day intake and same 
prescription dose as the prevention of cerebral embo-
lism from non-valvular atrial fibrillation are the advan-
tage of edoxaban. We treated a patient with cerebral 
sinus thrombosis with edoxaban alone as an outpatient. 
This is the first report of the treatment of cerebral sinus 
thrombosis with edoxaban alone.
Case Report
A previously healthy 47-year-old woman visited 
our hospital complaining of headache for the previous 
7 days. She had no remarkable medical history, like 
surgery, infection, trauma, pregnancy, of medication, 
except for anemia. She had had symptoms of a com-
mon cold and a fever of 38 °C from 7 days earlier. Her 
fever disappeared quickly, but her headache did not im-
prove despite taking analgesics.
Physical and neurological examinations showed no 
abnormalities. Her blood pressure and body temperature 
were within normal range. Brain Computed Tomography 
(CT) showed no brain lesion except for high density from 
the right lateral to sigmoid sinus (Figure 1). Brain Ma-
gnetic Resonance (MR) imaging and MR angiography 
also showed no brain or arterial abnormalities. T1- and 
T2-weighted images showed isointensity and loss of 
flow void at the right lateral and sigmoid sinus, and T2* 
image revealed low intensity thrombosis from the right 
lateral to sigmoid sinus (Figure 2). MR venography did 
not demonstrate flow of the right lateral to sigmoid 
sinus (Figure 3). A blood examination showed anemia 
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As initial therapy for cerebral sinus thrombosis, heparin in-
jection and subsequent oral anticoagulant, namely warfarin, 
has been recommended. We treated a patient with cerebral 
sinus thrombosis with edoxaban alone as an outpatient. 
This is the first report of cerebral sinus thrombosis being 
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symptoms, treatment with a DOAC at an outpatient clinic is 
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Introduction
Cerebral sinus thrombosis is a relatively rare di-
sease. Because the most frequent initial symptom is 
non-specific headache, the early diagnosis of cerebral 
sinus thrombosis is not easy. However, any delay in the 
diagnosis of cerebral sinus thrombosis is accompanied 
by severe symptom caused by cerebral damage and a 
poor prognosis.
As initial therapy for cerebral sinus thrombosis, he-
parin injection and subsequent oral anticoagulant, na-
mely warfarin, has been recommended [1]. Recently, 
Direct Oral Anticoagulants (DOACs) have demonstrated 
the same efficacy and better safety than warfarin for 
patients with deep venous thrombosis [2-4]. The clini-
cal effects and risks of DOACs for patients with cerebral 
venous or sinus thrombosis have not been established; 
however, better efficacy and safety than warfarin are 
expected. Indeed, there are some case reports of cere-
bral sinus thrombosis treated with dabigatran and riva-
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diogenic cerebral thrombosis and the prevention and 
treatment of deep venous thrombosis. The recommen-
ded initial treatment of deep venous thrombosis is con-
tinuous intravenous infusion of heparin under hospital 
admission and subsequent oral administration of an an-
ticoagulant [1]. However, the rationale supporting this 
recommendation is weak. A randomized controlled trial 
comparing heparin treatment with placebo for cerebral 
venous thrombosis showed a better outcome for hepa-
rin [5]. However, in that study, heparin administration 
was started late (20-30 days after onset). The study was 
preliminarily stopped and included only 20 patients. 
Another randomized controlled trial of 60 patients with 
cerebral venous thrombosis detected no significant dif-
ference between heparin and placebo [6].
Cerebral sinus thrombosis is a rare disease, and its 
early diagnosis is not easy. Therefore, a large control-
led study for cerebral sinus thrombosis may be difficult. 
Recently several types of DOAC have become available. 
The non-inferiority of DOACs against heparin plus war-
farin for the prevention and treatment of deep venous 
thrombosis has been reported [2-4]. The clinical efficacy 
and mild elevation of Fibrinogen Degradation Products 
(FDP), d-dimer and C-reactive Protein (CRP). Because 
her only symptom was a headache with no neurologi-
cal abnormalities and she wished to be treated at an 
outpatient clinic, we prescribed the DOAC edoxaban at 
30 mg once daily. The usual dose of edoxaban for pa-
tients with venous thrombosis is 60 mg. However, this 
patient’s body weight was less than 50 kg, so a reduced 
daily dose of 30 mg was selected.
Her headache and high density at the sinus on brain CT 
disappeared within two weeks after starting edoxaban intake 
(Figure 1). A blood examination at one month after the start 
of edoxaban showed normalization of FDP and slight elonga-
tion of Prothrombin Time (PT) and Activated Partial Throm-
boplastin Time (APTT). Brain MR imaging and MR venography 
at two months after the start of edoxaban demonstrated re-
canalization of the occluded sinus (Figure 3). The prescription 
of edoxaban was terminated, and no symptoms have been 
reported since then.
Discussion
The indications of DOAC are the prevention of car-
         
Figure 1: Initial Brain CT (upper) showed high density from the right lateral to sigmoid sinus (arrows). This high density at the 
sinus disappeared within two weeks after the therapy (lower).
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Figure 2: Initial T1 (left) and T2 (middle) weighted images showed isointensity and loss of flow void at the right lateral and 
sigmoid sinus, and T2* image (Right) revealed low intensity thrombosis from the right lateral to sigmoid sinus (upper). MR 
imaging at two months after the start of edoxaban demonstrated recanalization of the occluded sinus (lower).
         
Figure 3: Initial MR venography did not demonstrate flow of the right lateral to sigmoid sinus (left). MR venography at two 
months after the start of edoxaban demonstrated recanalization of the occluded sinus (right).
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toms, treatment with a DOAC at an outpatient clinic is 
more effective in ensuring the patient’s QOL and redu-
cing medical costs.
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and risks of DOACs for patients with cerebral venous 
or sinus thrombosis has not been established; howe-
ver, greater efficacy and safety than with warfarin are 
expected.
There have been some case reports of cerebral sinus 
thrombosis being treated with dabigatran, rivaroxaban 
or edoxaban [7-10]. However, none of these case re-
ports were randomized controlled trials. Most of these 
reports used heparin as the initial therapy, and dabiga-
tran, rivaroxaban or edoxaban was effective and safe 
for these patients with cerebral sinus thrombosis.
To our knowledge, our case seems to be the first re-
port of cerebral sinus thrombosis treated with edoxa-
ban alone. We did not select heparin treatment as the 
initial therapy because the patient wished to be treated 
at an outpatient clinic. The efficacy and safety of our tre-
atment should be evaluated in a large systematic study. 
However, because of the rarity of cerebral sinus throm-
bosis and the difficulty of its early diagnosis, single case 
reports such as ours may be the only significant contri-
butors to decision-making for clinical practitioners.
The cost of 5000 units of heparin is 2000-3000 Ja-
panese Yen (approximately $18-27 US), and continuous 
heparin intravenous infusion therapy requires hospital 
admission. The cost of a 30 mg tablet of edoxaban is 748 
Japanese Yen (approximately $6.7 US), and the drug can 
be administered on an outpatient basis. Therefore, sin-
gle-drug treatment with edoxaban at an outpatient cli-
nic can omit hospital admission costs as well as save on 
medication costs. A propensity-matched cohort study of 
hemodynamically stable pulmonary embolism patients 
showed that outpatient treatment was associated with 
a lower rate of adverse events than hospitalization [11]. 
During oral outpatient treatment with edoxaban, pa-
tients can continue their daily life, so such therapy can 
help ensure patients’ Quality of Life (QOL).
Conclusion
We treated a patient with cerebral sinus thrombosis 
with edoxaban alone as an outpatient. This is the first 
report of cerebral sinus thrombosis being treated with 
edoxaban alone. For patients with mild cerebral venous 
or sinus thrombosis without severe neurological symp-
